195 related articles for article (PubMed ID: 24603724)
1. TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.
Komar-Stossel C; Gross E; Dery E; Corchia N; Meir K; Fried I; Abramovitch R
PLoS One; 2014; 9(3):e90224. PubMed ID: 24603724
[TBL] [Abstract][Full Text] [Related]
2. TL-118-anti-angiogenic treatment in pancreatic cancer: a case report.
Breuer S; Maimon O; Appelbaum L; Peretz T; Hubert A
Med Oncol; 2013; 30(2):585. PubMed ID: 23609193
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax-based Rational Combinations are Effective in Models of
Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC
Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831
[TBL] [Abstract][Full Text] [Related]
4. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
5. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
[TBL] [Abstract][Full Text] [Related]
7. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
8. 2-Deoxyglucose treatment complements the cisplatin- or BH3-only mimetic-induced suppression of neuroblastoma cell growth.
Chuang JH; Chou MH; Tai MH; Lin TK; Liou CW; Chen T; Hsu WM; Wang PW
Int J Biochem Cell Biol; 2013 May; 45(5):944-51. PubMed ID: 23395630
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
Li H; Yu Y; Zhao Y; Wu D; Yu X; Lu J; Chen Z; Zhang H; Hu Y; Zhai Y; Su J; Aheman A; De Las Casas A; Jin J; Xu X; Shi Z; Woodfield SE; Vasudevan SA; Agarwal S; Yan Y; Yang J; Foster JH
Cancer Lett; 2019 Aug; 457():129-141. PubMed ID: 31100410
[TBL] [Abstract][Full Text] [Related]
10. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
[TBL] [Abstract][Full Text] [Related]
11. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.
Hogarty MD; Norris MD; Davis K; Liu X; Evageliou NF; Hayes CS; Pawel B; Guo R; Zhao H; Sekyere E; Keating J; Thomas W; Cheng NC; Murray J; Smith J; Sutton R; Venn N; London WB; Buxton A; Gilmour SK; Marshall GM; Haber M
Cancer Res; 2008 Dec; 68(23):9735-45. PubMed ID: 19047152
[TBL] [Abstract][Full Text] [Related]
12. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells.
Wang J; Gu S; Huang J; Chen S; Zhang Z; Xu M
BMC Cancer; 2014 Oct; 14():768. PubMed ID: 25323222
[TBL] [Abstract][Full Text] [Related]
14. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
15. Catastrophic ATP loss underlies a metabolic combination therapy tailored for
Dalton KM; Lochmann TL; Floros KV; Calbert ML; Kurupi R; Stein GT; McClanaghan J; Murchie E; Egan RK; Greninger P; Dozmorov M; Ramamoorthy S; Puchalapalli M; Hu B; Shock L; Koblinski J; Glod J; Boikos SA; Benes CH; Faber AC
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33762304
[No Abstract] [Full Text] [Related]
16. GX15-070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma.
Cournoyer S; Addioui A; Belounis A; Beaunoyer M; Nyalendo C; Le Gall R; Teira P; Haddad E; Vassal G; Sartelet H
BMC Cancer; 2019 Oct; 19(1):1018. PubMed ID: 31664947
[TBL] [Abstract][Full Text] [Related]
17. Tumor origin of endothelial cells in human neuroblastoma.
Pezzolo A; Parodi F; Corrias MV; Cinti R; Gambini C; Pistoia V
J Clin Oncol; 2007 Feb; 25(4):376-83. PubMed ID: 17264333
[TBL] [Abstract][Full Text] [Related]
18. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model.
Zhou S; Yang Y; Yang Y; Tao H; Li D; Zhang J; Jiang G; Fang J
PLoS One; 2013; 8(7):e68589. PubMed ID: 23874680
[TBL] [Abstract][Full Text] [Related]
20. Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma.
Bierau J; van Gennip AH; Leen R; Meinsma R; Caron HN; van Kuilenburg AB
Cancer Chemother Pharmacol; 2006 Jan; 57(1):105-13. PubMed ID: 16133534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
